Judgment of the National Green Tribunal in the matter of Shalbjit Singh Vs Punjab State Pollution Control Board & Others dated 21/11/2024. A letter petition dated November 5, 2022 was sent by Shalabhjeet Singh, resident of village Haibatpur, tehsil Derabassi, district SAS Nagar, Mohali complaining that M/s Nectar Life Sciences …
Ranbaxy Laboratories, set to be merged with Sun Pharmaceutical Industries, might again have to pay a hefty penalty to the US authorities for alleged violations at its Toansa factory in Punjab. The facility is currently banned from supplying products to the American market. According to a regulatory source, an administrative …
In yet another twist to the Ranbaxy scandal, the drug regulatory authority of the UK government has issued a statement clarifying that they have found no evidence that any of Ranbaxy’s products in the UK market “are or have been of unacceptable quality”. The World Health Organisation (WHO) had issued …
Analysts say the new mechanism would impact revenues in the short term only The Indian pharmaceutical industry is likely to see a dip in valuations in the near term as a result of the recent pricing policy that aims to intensify the regulatory hold over essential drugs. Profit of major …
Accepts GoM's final recommendations without changes, say sources The Cabinet today endorsed the recommendations of a Group of Ministers’ (GoM) on a revised National Pharmaceutical Pricing Policy, giving shape to a long-pending issue. The government did not give out details of the decision. According to sources, the Cabinet has imposed …
GoM had proposed a new pricing mechanism, but judges had said at an earlier hearing the current formula should stay The government is likely to formally tell the Supreme Court about the need to change the existing drug pricing mechanism. At the previous hearing on the issue last Wednesday, SC …
New Delhi The government is planning to tighten the regulatory landscape of the R4,500-crore vitamins and neutraceuticals market in the country. Different arms of government — the drug regulator, Drug Controller General of India (DCGI), and the food regulator, Food Safety and Standards Authority of India (FSSAI) — are taking …
New Delhi A suo motu study on drug pricing by the Ministry of Corporate Affairs has revealed exorbitant profit margins on 21 common drugs manufactured by Indian companies. Though pricing regulations of the National Pharmaceutical Pricing Authority (NPPA) say that companies can keep a profit margin of maximum 100 per …
A suo motu study on drug pricing by the Ministry of Corporate Affairs has revealed exorbitant profit margins on 21 common drugs manufactured by Indian companies. Though pricing regulations of the National Pharmaceutical Pricing Authority (NPPA) say that companies can keep a profit margin of maximum 100 per cent over …
This move could cost $299 million a year for Indian pharma players All generic pharmaceutical companies, including Ranbaxy Laboratories, Cipla, Dr Reddy’s Laboratories, Lupin, Glenmark and Torrent Pharma, might soon have to pay a fee to the US drug regulator when they seek its permission to sell their products there. …
Leading pharma companies including GlaxoSmithkline, Pfizer and Ranbaxy sell commonly used drugs at a rate 10 times the cost of production, a study by the Corporate Affairs Ministry has found. A study by the Cost Audit branch of the MCA found drugs like Calpol manufactured by Glaxosmithkline, Corex Cough Syrup …
Liberalisation measures in the pharmaceutical sector have brought about major changes in the industrial licensing policy, import restrictions, foreign direct investment and production controls. It was feared that firms would shift from indigenous production to imports, especially of bulk drugs, and this concern was aggravated with the change in the …
India on Wednesday launched its first indigenously manufactured anti-malaria new-age drug Synriam. The drug, produced by Ranbaxy Laboratories, was formally introduced for marketing here. The drug, launched by Health Minister Ghulam Nabi Azad in the presence of Science and Technology Minister Vilasrao Deshmukh, has been developed by the company in …
New Delhi: India has developed a powerful new malaria drug — an alternative to the global drug of choice Artemisinin — that promises to be a major boost to India’s pharmaceutical research. The new drug’s raw materiel is synthetic (derived chemically in the lab) while Artemisinin is derived from a …
Bombay HC refuses to stay 1996 notice to 500 companies on overcharging for bulk drugs More than 500 Indian drug companies will have to collectively pay over . 4,000 crore in dues after a high court shot down their petition challenging penalty notices sent by drug authorities for overcharging. Special …
Mumbai: Japanese drug major Daiichi has lowered its profit forecast for the year ending March 2012, and slashed senior executive pay, to offset the impending loss arising out of its Indian subsidiary, Ranbaxy’s $500-million legal settlement in the US. After months of sticky negotiations, Ranbaxy finally announced on Wednesday that …
The Lipitor incident provides us with some insight into the pharmaceutical world, where science rubs shoulders with greed and intrigue On Wednesday, Ranbaxy put out an advertisement in the newspapers thanking everyone for their support in developing and launching atorvastatin in the US, which is the generic equivalent of Pfizer’s …
Cholesterol Drug Hits US Stores The Day Pfizer Loses Patent Protection Mumbai: India’s largest drug company, Ranbaxy, which had been chasing a dream for years to launch the first generic version of world’s top-selling medicine Lipitor in the US, has finally succeeded—and, that too, as per schedule. Ending months of …
Lipitor goes off patent today, but Pfizer may’ve queered pitch for clones, impacting Ranbaxy-led Indian pharma Indian pharma companies’ quest to make millions from the sale of copycat versions of blockbuster drugs may turn out to be a flop show as innovative companies raise defences to protect their turf. The …
India’s attempts to check foreign investment in pharma and expand drug pricing control could force multinationals to exit the country, the head of Pfizer India has warned. “India might not become attractive market if we have such controls, you will see companies pulling out of India,” Kewal Handa, the managing …
Even as India’s largest drug maker, Ranbaxy, is confident of launching its first “new drug” by January 2012 to combat malaria in the country, the global euphoria the potential drug had generated in the initial stages of its research seems missing. Health experts attribute this to the absence of international …
